Results 51 to 60 of about 20,100 (304)

Complement blockade for TA-TMA: lessons learned from large pediatric cohort treated with eculizumab.

Blood, 2020
Overactivated complement is a high-risk feature in HSCT recipients with transplant associated thrombotic microangiopathy (TA-TMA), and untreated patients have dismal outcomes.
S. Jodele, C. Dandoy, A. Lane, B. Laskin, Ashley Teusink‐Cross, K. Myers, G. Wallace, A. Nelson, J. Bleesing, Ranjit S Chima, R. Hirsch, T. Ryan, S. Benoit, Kana Mizuno, Mikako Warren, S. Davies   +15 more
semanticscholar   +1 more source

Eculizumab: another breakthrough [PDF]

Blood, 2017
In this issue of Blood, Harder et al demonstrate that breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with eculizumab is due to strong activation of the complement cascade, leading to higher C3b density, which may cause a conformation change limiting the ability of eculizumab to block terminal complement ...
openaire   +2 more sources

Eculizumab for the treatment of myasthenia gravis

Expert Opinion on Biological Therapy, 2020
Acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG) is effectively treated with symptomatic and immunosuppressive drugs but a proportion of patients has a persistent disease and severe adverse events (AEs). The unmet medical needs are specific immunosuppression and AE lowering.
Renato Mantegazza, Paola Cavalcante
openaire   +3 more sources

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

BMC Nephrology, 2021
Background Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the
Maximilien Grall, Florence Daviet, Noémie Jourde Chiche, François Provot, Claire Presne, Jean-Philippe Coindre, Claire Pouteil-Noble, Alexandre Karras, Dominique Guerrot, Arnaud François, Ygal Benhamou, Agnès Veyradier, Véronique Frémeaux-Bacchi, Paul Coppo, Steven Grangé   +14 more
doaj   +1 more source

Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment [PDF]

, 2017
Los datos asociados con este artículo están disponibles en: http://dx.doi.org/10.1016/j.imbio.2016.09.002.Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia characterized by complement-mediated intravascular hemolysis that is ...
Anter, Jaouad, Ataúlfo Gonzalez-Fernández, Fernando, Forés, Rafael, García, Sheila Pinto, López, Alicia, López-Trascasa, Margarita, Martin Merinero, Hector, Ojeda, Emilio, Rodríguez de Córdoba, Santiago, Subías Hidalgo, Marta, Villegas, Ana   +10 more
core   +2 more sources

Eculizumab for refractory thrombosis in antiphospholipid syndrome [PDF]

Blood Advances, 2020
Abstract Antiphospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis with antiphospholipid antibodies. Dysregulation of the complement pathway has been implicated in APS pathophysiology. We report the successful use of eculizumab, an anti-C5 monoclonal antibody, in controlling and preventing recurrent thrombosis
Habiba Hussain, Michael D. Tarantino, Shruti Chaturvedi, Keith R. McCrae, Jonathan C. Roberts   +4 more
openaire   +3 more sources

Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy

Frontiers in Pediatrics, 2021
Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT) associated with high morbidity and mortality. High-risk TA-TMA (hrTA-TMA) is characterized by multifactorial
Laura Gomez-Ganda, Maria Isabel Benitez-Carabante, Aurora Fernandez-Polo, Marina Muñoz-Lopez, Berta Renedo-Miro, Gema Ariceta, Cristina Diaz De Heredia   +6 more
doaj   +1 more source

Disseminated Cryptococcosis Following Eculizumab Therapy: Insight Into Pathogenesis

Open Forum Infectious Diseases, 2023
Eculizumab, a recombinant humanized monoclonal antibody (mAb), is used for the treatment of patients (both adults and children) with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
O. Lortholary, Carine El-Sissy, J. Leporrier, Sarah Sze Wah Wong, E. Dannaoui, V. Frémeaux-Bacchi, V. Aimanianda   +6 more
semanticscholar   +1 more source

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes [PDF]

, 2017
C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients, may undergo extravascular hemolysis ...
A Hill, A Hill, A Nicholson-Weller, A Roth, AM Risitano, AM Risitano, AM Risitano, AM Risitano, AM Risitano, Antonio M. Risitano, B Nilsson, CE Schoot van der, DJ Araten, DS Holt, E Lach-Trifilieff, E Marchiafava, G Gronowicz, GL Logue, GV Seaman, J Nishimura, J Takeda, JD Tamerius, JE May, JP Atkinson, JV Dacie, L Luzzatto, L Luzzatto, L Luzzatto, M Bessler, M Harboe, M Kono, M Loschi, M Sica, M Sica, MA Lindorfer, Maria De Angioletti, MH Holguin, Michela Sica, MJ Harder, MK Pangburn, MK Pangburn, P Hillmen, P Hillmen, P Hillmen, Patrizia Ricci, PJ Lachmann, PJ Lachmann, RJ Kelly, RL Sparrow, Rosario Notaro, RP Latour de, RP Rother, S Berentsen, SK Krishnan, T Olutogun, T Rondelli, TH Ham, Tommaso Rondelli, UM Reiss, VM Holers, VP Ferreira, WF Rosse, WF Rosse, Z Fishelson, Z Lin   +64 more
core   +2 more sources

Eculizumab in Atypical Hemolytic–Uremic Syndrome [PDF]

New England Journal of Medicine, 2013
To the Editor: With regard to the article by Legendre et al. (June 6 issue)(1): assessment of the 37 patients with atypical hemolytic-uremic syndrome is difficult, since the process of selection seems opaque, particularly for the 20 patients in trial 2.
Christophe Legendre, Christoph Licht, Chantal Loirat   +2 more
openaire   +10 more sources